Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8222520 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL2133849 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL3669860 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL14191224 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL8320089 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL13646429 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL13630595 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL3793643 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL3793642 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 | |
| SCHEMBL11894637 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCYP3A4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526769-B2 | Macrocylic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9309279-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140148573-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8268776-B2 | mixture of cytochrome P450 monooxygenase inhibitor and protease inhibitor for anti-hepatitis C viral treatment; including other active drugs as interferon, ribavarin, and adamantine | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-RE42375-E1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7718612-B2 | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090035272-A1 | Pyridazinonyl Macrocyclic Hepatitis C Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20080279821-A1 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080181868-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-07-31 | — | — | US | disclosed |
| US-20080152622-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC | 2008-06-26 | — | — | US | disclosed |
| US-20070281884-A1 | Macrocyclic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148573-A1 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS15, PRSS1, SPINT2 | ADRB3 3933/4885ADRA2B 4558/4885ADRA2C 3776/4885 |
| US-20090035272-A1 | Pyridazinonyl Macrocyclic Hepatitis C Serine Protease Inhibitors | PRSS1, SPINT2, TMPRSS4 | ADRB3 4135/4885ADRA2B 4438/4885ADRA2C 3858/4885 |
| US-20080279821-A1 | ARYLPIPERIDINYL AND ARYLPYRROLIDINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, CTSC, SPINT2 | ADRB3 4060/4885ADRA2B 4318/4885ADRA2C 3177/4885 |
| US-20080181868-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | HCCS, CPN1, HPN | ADRB3 4555/4885ADRA2B 4689/4885ADRA2C 4493/4885 |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | HCCS, CPN1, HPN | ADRB3 4555/4885ADRA2B 4689/4885ADRA2C 4493/4885 |
| US-20070281884-A1 | Macrocyclic oximyl hepatitis C protease inhibitors | HCCS, HPN, CYP3A4 | ADRB3 4424/4885ADRA2B 4659/4885ADRA2C 4207/4885 |
| US-20080152622-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, HPN | ADRB3 4665/4885ADRA2B 4704/4885ADRA2C 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.